Clinical trial
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With…
NCT00375427 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00375427 |
|---|---|
| Title | Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions |
| Official title | A Prospective, Randomized, Multi-center Comparative 2-arm Trial of Efficacy and Safety of Zoledronic Acid (Every 3-months vs. Every 4 Weeks) Beyond Approximately 1 Year of Treatment With Zoledronic Acid in Patients With Bone Lesions From Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer With Bone Metastasis |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 430 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2010 |
| First posted | Sep 13, 2006 |
| Last update posted | Apr 11, 2012 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: